William Berry

1000 total citations
16 papers, 675 citations indexed

About

William Berry is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, William Berry has authored 16 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 6 papers in Surgery and 6 papers in Oncology. Recurrent topics in William Berry's work include Prostate Cancer Treatment and Research (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). William Berry is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). William Berry collaborates with scholars based in United States, Australia and United Kingdom. William Berry's co-authors include Kenneth P. Nephew, Yan Zeng, Tim H.‐M. Huang, Fang Fang, Changyu Shen, Jeanne M. Schilder, Daniela Matei, Fabio Calabrò, Daniel P. Petrylak and Nicholas D. James and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

William Berry

16 papers receiving 663 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William Berry United States 8 297 252 226 164 76 16 675
Sasja F. Mulder Netherlands 12 265 0.9× 340 1.3× 253 1.1× 130 0.8× 51 0.7× 38 669
Joline S.J. Lim Singapore 14 303 1.0× 144 0.6× 392 1.7× 162 1.0× 129 1.7× 56 805
Elisa Zanardi Italy 16 177 0.6× 420 1.7× 355 1.6× 170 1.0× 102 1.3× 56 785
M. Puglisi Italy 16 257 0.9× 408 1.6× 539 2.4× 68 0.4× 44 0.6× 38 998
Aranzazu González del Alba Spain 15 359 1.2× 510 2.0× 274 1.2× 280 1.7× 88 1.2× 79 870
Jaume Capdevila Spain 18 150 0.5× 158 0.6× 277 1.2× 59 0.4× 101 1.3× 41 1.0k
Deanna McLeod Canada 15 222 0.7× 229 0.9× 461 2.0× 224 1.4× 52 0.7× 26 793
A. McDonald United Kingdom 14 210 0.7× 203 0.8× 409 1.8× 127 0.8× 46 0.6× 19 721
W. Thomas Purcell United States 16 244 0.8× 518 2.1× 534 2.4× 184 1.1× 83 1.1× 40 935
A. Van Oosterom Belgium 11 228 0.8× 209 0.8× 268 1.2× 124 0.8× 23 0.3× 28 572

Countries citing papers authored by William Berry

Since Specialization
Citations

This map shows the geographic impact of William Berry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Berry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Berry more than expected).

Fields of papers citing papers by William Berry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Berry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Berry. The network helps show where William Berry may publish in the future.

Co-authorship network of co-authors of William Berry

This figure shows the co-authorship network connecting the top 25 collaborators of William Berry. A scholar is included among the top collaborators of William Berry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Berry. William Berry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Appleman, Leonard J., William Berry, Howard Gurney, et al.. (2021). 347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up. SHILAP Revista de lepidopterología. A374–A374. 1 indexed citations
2.
Piulats, Josep M., Cristiano Ferrario, Mark Linch, et al.. (2021). 351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). SHILAP Revista de lepidopterología. A378–A378. 3 indexed citations
3.
Yu, Evan Y., Peter C.C. Fong, Josep M. Piulats, et al.. (2020). PD16-12 PEMBROLIZUMAB PLUS ENZALUTAMIDE IN ABIRATERONE-PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: UPDATED RESULTS FROM KEYNOTE-365 COHORT C. The Journal of Urology. 203(Supplement 4). 6 indexed citations
4.
Berry, William, Benjamin S. Daniel, Christopher M. Baker, & Peter Foley. (2020). Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry. Australasian Journal of Dermatology. 61(4). 380–382. 3 indexed citations
5.
Seitz, Lisa, William Berry, Daniel DiRenzo, et al.. (2018). Preliminary results from a phase 1 study of AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced solid malignancies. Annals of Oncology. 29. x28–x28. 1 indexed citations
6.
Priemer, David S., William Berry, Dean A. Hawley, & Harvey Cramer. (2018). Death within 30 days of fine needle aspiration: Post‐mortem confirmation of FNA diagnoses and the contribution of FNA to patient mortality. Diagnostic Cytopathology. 46(12). 993–1003. 1 indexed citations
7.
Cheng, Yao‐Wen, Kumar Sandrasegaran, Marwan Ghabril, et al.. (2017). A dedicated paracentesis clinic decreases healthcare utilization for serial paracenteses in decompensated cirrhosis. Abdominal Radiology. 43(8). 2190–2197. 8 indexed citations
8.
Sandrasegaran, Kumaresan, et al.. (2016). Risk factors for bleeding after liver biopsy. Abdominal Radiology. 41(4). 643–649. 15 indexed citations
9.
Jalal, Shadia I., Robert Matthew Strother, George E. Sandusky, et al.. (2013). Phase I study of everolimus (E, RAD001) and ganitumab (G, AMG 479) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2529–2529. 3 indexed citations
10.
Matei, Daniela, Fang Fang, Changyu Shen, et al.. (2012). Epigenetic Resensitization to Platinum in Ovarian Cancer. Cancer Research. 72(9). 2197–2205. 302 indexed citations
11.
Sanyal, Rupan, Chandana Lall, Ramit Lamba, et al.. (2012). Orthotopic Liver Transplantation: Reversible Doppler US Findings in the Immediate Postoperative Period. Radiographics. 32(1). 199–211. 34 indexed citations
12.
Smith, Mitchell R., Emmanuel S. Antonarakis, Charles J. Ryan, et al.. (2012). ARN-509 in Men with High Risk Non-Metastatic Castration-Resistant Prostate Cancer. Annals of Oncology. 23. ix303–ix303. 9 indexed citations
13.
Sternberg, Cora N., Daniel P. Petrylak, Oliver Sartor, et al.. (2009). Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial. Journal of Clinical Oncology. 27(32). 5431–5438. 262 indexed citations
14.
Sartor, Oliver, Daniel P. Petrylak, C. Sternberg, et al.. (2009). Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial. Journal of Clinical Oncology. 27(15_suppl). 5148–5148. 1 indexed citations
15.
Sandrasegaran, Kumaresan, Chandana Lall, William Berry, Tariq Hameed, & Dean D. T. Maglinte. (2006). Enteric drainage pancreatic transplantation. Abdominal Imaging. 31(5). 588–595. 14 indexed citations
16.
Ferraris, Victor A., et al.. (1987). Verapamil Prophylaxis for Postoperative Atrial Dysrhythmias: A Prospective, Randomized, Double-blind Study Using Drug Level Monitoring. The Annals of Thoracic Surgery. 43(5). 530–533. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sasja F. Mulder Breakdown of academic impact, for papers by Joline S.J. Lim Breakdown of academic impact, for papers by Elisa Zanardi Breakdown of academic impact, for papers by M. Puglisi Breakdown of academic impact, for papers by Aranzazu González del Alba Breakdown of academic impact, for papers by Jaume Capdevila Breakdown of academic impact, for papers by Deanna McLeod Breakdown of academic impact, for papers by A. McDonald Breakdown of academic impact, for papers by W. Thomas Purcell Breakdown of academic impact, for papers by A. Van Oosterom
Rankless by CCL
2026